when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

1,498 stories

Sep 9, 26Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stockfiercebiotech

Sep 9, 26Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyfiercebiotech

Sep 9, 26STAT+: Can AI fix health care? In the chaos of emergency rooms, the technology comes up shortstat

Sep 9, 26Opinion: AMA CEO: AI won’t replace doctors — it will work alongside themstat

Sep 9, 26Beyond China: Five other overseas destinations for biopharma dollarsbiospace

Sep 9, 26Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2fiercebiotech

Sep 8, 26STAT+: FDA names acting heads of drug and vaccine centers to permanent rolesstat

Sep 8, 26Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapybiopharma dive

Sep 8, 26Amgen’s T cell engager notches new major lung cancer victoryendpoints

Sep 8, 26STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandalsstat

Sep 8, 26Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12endpoints

Sep 8, 26STAT+: UnitedHealth’s Democrat investment, and surprise billing bloat debatestat

Sep 8, 26Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerbiospace

Sep 8, 26STAT+: Health care features prominently in Democrats’ agendastat

Sep 8, 26Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 databiospace

Sep 8, 26STAT+: Oura files to goes public, reported $1.2B in earningsstat

Sep 8, 26STAT+: FDA approves AstraZeneca breast cancer drugstat

Sep 8, 26Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-Tendpoints

Sep 8, 26STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and morestat

Sep 8, 26AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerbiospace

Sep 8, 26Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinicbiospace

Sep 8, 26STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studiesstat

Sep 8, 26An administrative gap delays access to new pancreatic cancer treatmentstat

Sep 8, 26Inhibrx targets OX40 agonist-cancer vaccine studies from early next yearendpoints

Sep 8, 26STAT+: Inhibrx claims first win for long-sought immunotherapy targetstat

Sep 8, 26BrainChild Bio targets deadly pediatric brain cancer with $116M series Abiospace

Sep 8, 26BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-Tendpoints

Sep 8, 26BrainChild hauls in $116M to make cell therapies for childhood brain cancersbiopharma dive

Sep 8, 26FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerfiercebiotech

Sep 8, 26Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointfiercebiotech

← prevpage 13 of 50next →